Whitehawk Therapeutics, Inc. (WHWK) - Total Liabilities
Based on the latest financial reports, Whitehawk Therapeutics, Inc. (WHWK) has total liabilities worth $9.85 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Whitehawk Therapeutics, Inc. annual equity growth to track the company's year-over-year net asset growth rate.
Whitehawk Therapeutics, Inc. - Total Liabilities Trend (2019–2024)
This chart illustrates how Whitehawk Therapeutics, Inc.'s total liabilities have evolved over time, based on quarterly financial data. See free cash flow generation of Whitehawk Therapeutics, Inc. to measure how efficiently the company converts operating cash flow to free cash.
Whitehawk Therapeutics, Inc. Competitors by Total Liabilities
The table below lists competitors of Whitehawk Therapeutics, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Astra Graphia Tbk
JK:ASGR
|
Indonesia | Rp895.27 Billion |
|
Coraza Integrated Technology Bhd
KLSE:0240
|
Malaysia | RM83.55 Million |
|
ChargePoint Holdings Inc
NYSE:CHPT
|
USA | $730.09 Million |
|
Well Shin Technology Co Ltd
TW:3501
|
Taiwan | NT$2.67 Billion |
|
TIZIANA LIFE SCIENCES LTD
F:0RP
|
Germany | €7.35 Million |
|
Waton Financial Limited Ordinary Shares
NASDAQ:WTF
|
USA | $5.31 Million |
|
Den Networks Limited
NSE:DEN
|
India | Rs4.57 Billion |
|
TRUFIN PLC
F:29U
|
Germany | €14.17 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Whitehawk Therapeutics, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Whitehawk Therapeutics, Inc. (WHWK) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 16.76 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Whitehawk Therapeutics, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Whitehawk Therapeutics, Inc. (2019–2024)
The table below shows the annual total liabilities of Whitehawk Therapeutics, Inc. from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $17.84 Million | -34.48% |
| 2023-12-31 | $27.23 Million | +5.29% |
| 2022-12-31 | $25.86 Million | +20.25% |
| 2021-12-31 | $21.50 Million | -31.20% |
| 2020-12-31 | $31.26 Million | +21.38% |
| 2019-12-31 | $25.75 Million | -- |
About Whitehawk Therapeutics, Inc.
Whitehawk Therapeutics, Inc., an oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides a three-asset antibody-drug conjugate (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in March 2025. Whitehawk Therapeutics, Inc. was incorporated in 200… Read more